NVL-330
- Generic Name
- NVL-330
A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Phase 1
Recruiting
- Conditions
- Locally Advanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Nuvalent Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06521554
- Locations
- 🇺🇸
City of Hope - Lennar, Irvine, California, United States
🇺🇸OSU Brain and Spine Hospital, Columbus, Ohio, United States
🇦🇺North Shore Health Hub, Saint Leonards, New South Wales, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath